Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
NCP Cross, HE White, D Colomer, H Ehrencrona… - Leukemia, 2015 - nature.com
Abstract Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has
advanced to a stage where many patients achieve very low or undetectable levels of …
advanced to a stage where many patients achieve very low or undetectable levels of …
Monitoring of minimal residual disease (MRD) in chronic myeloid leukemia: recent advances
C Cumbo, L Anelli, G Specchia… - Cancer management and …, 2020 - Taylor & Francis
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR-ABL1
fusion gene generation as a consequence of the t (9; 22)(q34; q11) rearrangement. The …
fusion gene generation as a consequence of the t (9; 22)(q34; q11) rearrangement. The …
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study
HE White, M Salmon, F Albano, CSA Andersen… - Leukemia, 2022 - nature.com
Standardized monitoring of BCR:: ABL1 mRNA levels is essential for the management of
chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and …
chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and …
A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR
H White, L Deprez, P Corbisier, V Hall, F Lin, S Mazoua… - Leukemia, 2015 - nature.com
Serial quantification of BCR–ABL1 mRNA is an important therapeutic indicator in chronic
myeloid leukaemia, but there is a substantial variation in results reported by different …
myeloid leukaemia, but there is a substantial variation in results reported by different …
Best practices in chronic myeloid leukemia monitoring and management
S Soverini, C De Benedittis, M Mancini… - The oncologist, 2016 - academic.oup.com
Optimal use of current therapeutic opportunities for chronic myeloid leukemia patients
requires integration of clinical and laboratory monitoring. Assessment of molecular response …
requires integration of clinical and laboratory monitoring. Assessment of molecular response …
[HTML][HTML] Molecular techniques for the personalised management of patients with chronic myeloid leukaemia
Chronic myeloid leukemia (CML) is the paradigm for targeted cancer therapy. RT-qPCR is
the gold standard for monitoring response to tyrosine kinase-inhibitor (TKI) therapy based on …
the gold standard for monitoring response to tyrosine kinase-inhibitor (TKI) therapy based on …
Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization
NCP Cross, A Hochhaus, MC Müller - Annals of hematology, 2015 - Springer
Serial quantification of BCR-ABL1 messenger RNA (mRNA) is an important therapeutic
indicator for patients with chronic myeloid leukemia, but historically, there has been …
indicator for patients with chronic myeloid leukemia, but historically, there has been …
[HTML][HTML] A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on …
M Eckstein, RM Wirtz, C Pfannstil, S Wach, R Stoehr… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Background Immunohistochemical PD-L1 assessment is currently used to identify
responders towards checkpoint inhibitors although it is limited by inter-observer effects …
responders towards checkpoint inhibitors although it is limited by inter-observer effects …
Deep response in multiple myeloma: a critical review
M Fulciniti, NC Munshi… - BioMed research …, 2015 - Wiley Online Library
Novel and more effective treatment strategies against multiple myeloma (MM) have
significantly prolonged patients' survival and raised interest in the depth of response and its …
significantly prolonged patients' survival and raised interest in the depth of response and its …
Accurate quantitation of JAK 2 V617F allele burden by array‐based digital PCR
E Kinz, A Leiherer, AH Lang, H Drexel… - … Journal of Laboratory …, 2015 - Wiley Online Library
Summary Introduction The JAK 2 V617F mutation is highly prevalent in patients with
myeloproliferative neoplasms (MPN). Several studies have shown that allele burden …
myeloproliferative neoplasms (MPN). Several studies have shown that allele burden …